drugset / Trial / NCT02425176
Botulinum Toxin-A for Sialorrhoea Treatment in Asian Adults With Neurological Diseases
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The efficacy of Botulinum toxin A (BoNT-A) in Asian population has not been properly studied and there is no literature available on the most efficacious dose of BoNT-A for sialorrhoea treatment. This research is aimed to find the dose of Dysport® that would be efficacious without treatment-related adverse events and the duration of effectiveness of the drug for sialorrhea treatment in Malaysian patients. The efficacy, safety, tolerability and adverse effects of three doses of Dysport®(50MU, 100MU and 200MU) are examined at 2,6,12 and 24 weeks post injection in this double-blinding, randomized trial.
Timeline
- Start
- 2009-09
- Primary completion
- 2014-02
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Botulinum toxin type A | Protein / enzyme biologic | 50 iu | Other |
| Comparator | Botulinum toxin type A | Protein / enzyme biologic | 100 iu | Other |
| Comparator | Botulinum toxin type A | Protein / enzyme biologic | 200 iu | Other |
Indications
No indication recorded.